-
May 10, 2023 MindMed: Can the Former Darlings of the Psychedelic Biotech Sector Avoid Collapse?After MindMed's up-listing, the company has been facing a lot of instability and turbulence in...
-
April 24, 2023 Phase II Study Shows LSD Is Effective In Treating Major Depressive DisorderData from a Phase 2 clinical trial involving LSD-assisted psychotherapy show LSD as effective treatment...
-
October 6, 2022 Math Over Myth: Weekly Psychedelic Stocks News RoundupGet the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin...
-
September 30, 2022 Math Over Myth: September Psychedelic Stock News RoundupTrack the monthly performance of the psychedelic stock sector with our Math over Myth Stock...
-
September 28, 2022 Math Over Myth: MindMed’s Self Destructive Stock MissionPsychedelic stock MindMed enters free fall as news of a private equity offering of common...
-
September 14, 2022 Math Over Myth: Spotlight on MindMedIn the latest installment of Math Over Myth we navigate psychedelic stock MindMed’s reverse split...
-
August 19, 2022 Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine CollapsesThe psychedelic renaissance hits a rough patch as major companies look to tighten their belts...
-
August 15, 2022 MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts PipelineMindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is...
-
July 27, 2022 3 Microdosing Clinical Trials to Keep an Eye OnDoes microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical...
-
July 11, 2022 The Battle for Psychedelic PatentsPsychedelic companies rely on novel patents to boost their value, but many players in the...
